Ceftizoxime disposition in neonates and infants during the first six months of life
Reed, M.D.; Gooch, W.M.; Minton, S.D.; Tanaka-Kido, J.; Santos, J.I.; Yamashita, T.S.; Blumer, J.L.
Dicp the Annals of PharmacoTherapy 25(4): 344-347
ISSN/ISBN: 1042-9611 PMID: 1926899 DOI: 10.1177/106002809102500401
The single-dose pharmacokinetics of ceftizoxime sodium were studied in 52 neonates and infants between 0.1 and 189 days of age. Subjects received ceftizoxime 25 or 50 mg/kg iv over 15-30 minutes. The drug was administered q8-12h for five days to permit tolerance evaluation on repetitive dosing. No differences were observed in ceftizoxime pharmacokinetic parameter estimates relative to dose. However, marked differences were observed in ceftizoxime pharmacokinetic characteristics relative to infant age; ceftizoxime half-life and mean residence time decreased, whereas body clearance increased with infant age. Ceftizoxime volume of distribution remained relatively constant over infant age. No adverse effects associated with ceftizoxime administration were observed. These data suggest that ceftizoxime 50 mg/kg q12h be used for infants less than or equal to 2 weeks of age (less than or equal to 40 weeks postconceptional age) and that 50 mg/kg q8h be administered for older infants.